Publication date: Mar 04, 2019
Despite recent advances in the treatment of cancer, pancreatic ductal adenocarcinoma (PDAC) still retains the worst survival rate of common malignancies. Late diagnosis and lack of curative therapeutic options are the most pressing clinical problems for this disease. Therefore, there is a need for patient models and biomarkers that can be applied in the clinic to identify the most effective therapy for a patient. Pancreatic ductal organoids are ex-vivo models of PDAC that can be established from very small biopsies, enabling the study of localized, advanced, and metastatic patients. Organoids models have been applied to pancreatic cancer research and offer a promising platform for precision medicine approaches.
Tiriac, H., Plenker, D., Baker, L.A., and Tuveson, D.A. Organoid models for translational pancreatic cancer research. 04219. 2019 Curr Opin Genet Dev (54):
|Pancreatic Ductal Adenocarcinoma||Organoid|
|PDAC||Branches of biology|
- Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases.
- Systemic treatment for metastatic colorectal cancer in the era of precision medicine.
- Kidney Organoids in Translational Medicine: Disease Modeling and Regenerative Medicine.
- A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids.
- Proteomic and genomic profiling of pancreatic cancer.